Home Latest Articles
Latest Articles
  • Guoqin YANG, Yun WU, Jiaying KANG, Qing SUN
    World Clinical Drug. 2022, 43(2): 169-173.
    Objective

    To analyze the effects of Xinhuang tablets external application combined with Du Moxibustion on rheumatoid arthritis (RA).

    Methods

    A total of 80 RA patients admitted to Department of Rheumatology in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from July 2018 to March 2019 were selected as subjects. According to the random number table, patients were divided into the control group (celebrex+methotrexate+tripterygium glycoside) and the observation group, 40 cases in each group. The observation group were treated with Xinhuang tablets external application combined with Du Moxibustion on the basis of treatment in the control group, and the treatment course was 6 weeks. The short-term efficacy, long-term efficacy, pain visual analogue scale (VAS), traditional Chinese medicine (TCM) symptom score, blood erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) and adverse reactions during treatment were evaluated before treatment, 6 weeks after treatment and 6 months follow-up.

    Results

    After treatment, the short-term efficacy and long-term efficacy of the observation group were higher than those of the control group, and the differences were statistically significant (P<0.05). After 6 weeks of treatment, the VAS score, TCM symptom score, ESR, CRP and RF of the two groups were lower than those before treatment (P<0.05), and the VAS score, TCM symptom score, ESR, CRP and RF in the observation group were lower than the control group, and the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05).

    Conclusion

    External application of Xinhuang tablet combined with Du moxibustion in the treatment of RA can significantly reduce the inflammatory indexes such as ESR, CRP and RF, improve the short-term and long-term curative effect, relieve the degree of pain and effectively improve the symptoms.

  • Rong ZHANG, Ziwei TANG, Jing ZHAO, Sifan SUN, Chunyan LI, Ya HOU, Wei SUN
    World Clinical Drug. 2022, 43(2): 174-178.
    Objective

    To explore the effect of nutritional management in patients with chronic kidney disease.

    Methods

    A total of 534 patients admitted to Jiangsu Provincial Hospital of Traditional Chinese Medicine and the First People's Hospital of Jintang from January 2015 to December 2019 were selected. The 259 patients enrolled in nutritional management were included in the observation group, and 275 patients who did not enroll in nutritional management were included in the control group. The patients were followed up for 6 months and 12 months. The levels of hemoglobin, albumin, glomerular filtration rate, serum creatinine and uric acid of the two groups were compared.

    Results

    After 6 months and 12 months follow-up, the levels of hemoglobin and serum albumin in the observation group were significantly higher than those in the control group (P<0.05), and the hemoglobin level in the observation group was significantly higher than that in the control group at 6 months follow-up (P<0.05), while there was no significant difference in serum albumin level between the two groups after 12 months follow-up (P>0.05). At 6 and 12 months of follow-up, GFR in the observation group was significantly higher than that in the control group (P<0.05), while serum creatinine and uric acid in the observation group were significantly lower than those in the control group (P<0.05).

    Conclusion

    Nutritional management for patients with chronic kidney disease can significantly improve the patients’ nutritional status and delay the development of kidney disease.

  • Wenjie ZHU, Xiaoping WANG
    World Clinical Drug. 2022, 43(2): 179-182.
  • Siriguleng, Wudan, Luwen SHI
    World Clinical Drug. 2022, 43(2): 183-188.
  • Weili QIAO, Zhiguo SU, Fang LI
    World Clinical Drug. 2022, 43(2): 189-192.
  • Jiale LIU, Haifeng HU, Taoling MIN
    World Clinical Drug. 2022, 43(2): 193-199.

    The proper application of adjuvants in vaccines has the advantages of enhancing the immune response, prolonging the immune time, reducing the amount of antigen and overcoming the limited immune response in certain populations. There are many sources of adjuvants, and microorganism is one of the important sources. Microbial-derived adjuvants have the advantages of significantly promoting immune response, high stability and easy availability. At present, the widely used microbial vaccine adjuvants in clinical applications include BCG, virus particles, CpG-DNA, lipid A derivatives and so on. In this paper, the immune mechanism and clinical application progress of microbial adjuvants, microbial metabolites adjuvants and microbial nucleic acid adjuvants were reviewed in order to provide reference for the development of vaccine adjuvants derived from microorganisms.

  • Lu WANG, Yan REN, Ziwen DING, Jingyan ZHANG, Yiyun YUAN, Junlong WANG, Na NI
    World Clinical Drug. 2022, 43(2): 200-204.

    Loncastuximab tesirine-lpyl was approved by FDA on April 23, 2021. It is the first approved CD19 antibody coupled drug targeting pyrrolobenzodiazepine (PBD) dimer for the treatment of adult patients with recurrent or refractory large B-cell lymphoma who have received two or more systemic therapies. This paper mainly reviewed the clinical research progress of loncastuximab tesirine-lpyl in B-cell-derived malignant tumors, in order to provide a new reference for the clinical treatment of adult patients with recurrent or refractory large B-cell lymphoma.

  • Liuqing WANG, Yongwei WANG, Rongzhen XU
    World Clinical Drug. 2022, 43(2): 205-209.

    As an important immune checkpoint inhibitor, programmed cell death-1 (PD-1) is preferentially expressed in B cells, T cells and natural killer cell. PD-1 has two ligands: programmed death-ligand (PD-1)1 and PD-L2. PD-1 can prevent T cell over activation and down-regulate immune response, and plays an important role in reducing autoimmune response and promoting self tolerance. PD-1 signaling is used by tumors to escape immune killing. In recent years, a variety of PD-1 signaling inhibitors have been approved by FDA to induce anti-tumor immune response, which have achieved certain clinical efficacy, but many adverse drug reactions also occur in the treatment process. In this article, we reviewed the neuromuscular complications of PD-1 inhibitors in neurology in order to provide reference for standardized application of PD-1 inhibitors.

  • Jinxi DING, Wei LI
    World Clinical Drug. 2022, 43(1): 1-4.

    Since 2017, the national healthcare security administration (NHSA) has adjusted the national reimbursement drug list (NRDL) for five times. Normalized adjustment mechanism has been gradually established, and the negotiation mechanism has been increasingly improved. Especially in 2021, the NHSA, upholding integrity and innovation, made an all-round optimization of NRDL adjustment mechanism based on the full summary of the first four rounds of adjustment experience. This paper analyzed the policy optimization of NHSA in the fifth round of NRDL adjustment based on the practice of 2021 NRDL adjustment work, focusing on three aspects: access process, measurement mechanism, and adjustment principles. Furthermore, this paper summarized the experience and put forward development ideas to promote the further improvement of Chinese medical insurance system.

  • Zehao WANG, Dongqian SUN, Tianzuo LI, Guangtao XIA, Yong TANG
    World Clinical Drug. 2022, 43(1): 5-10.

    Glucocorticoid osteoporosis (GIOP) is the most common manifestation of secondary osteoporosis, which can cause serious adverse effects of the patients' health. The pathological mechanism of GIOP is complex. The effects of glucocorticoids on osteoblasts, osteoclasts and osteoblasts are different. At present, the understanding of GIOP is not completely clear. This paper reviewed the research progress on the pathogenesis of GIOP in recent years to help clarify the treatment methods of GIOP and develop new and effective treatment methods, which is of great significance to reduce the economic burden of individuals and society.

News